Trials / Recruiting
RecruitingNCT06213324
Neural Circuit Effects of Ketamine in Depression
Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRI
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine | 0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously |
| DRUG | Placebo | Normal saline delivered intravenously |
Timeline
- Start date
- 2024-01-31
- Primary completion
- 2028-03-30
- Completion
- 2028-04-30
- First posted
- 2024-01-19
- Last updated
- 2025-07-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06213324. Inclusion in this directory is not an endorsement.